Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
Excerpt:...- Patient must have confirmed HER2 overexpression or gene-amplified tumor via immunohistochemistry [IHC] with IHC 3+ or IHC 2+ with confirmatory fluorescence in situ hybridization [FISH]+ or [ISH]+...
Evidence Level:Sensitive: C3 – Early Trials
Title:
Role of HER2 copy number amplification and PI3K pathway as a biomarker for patients with HER2+ MBC treating with Poziotinib, pan-HER TKI.
Excerpt:HER2 CN amplification and PIK3CA pathway alteration had an effect on the clinical outcome of patients with HER2+ MBC treated with poziotinib.
DOI:10.1200/JCO.2018.36.15_suppl.e13009